ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CEL Celadon Pharmaceuticals Plc

61.00
1.50 (2.52%)
22 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Celadon Pharmaceuticals Plc LSE:CEL London Ordinary Share GB00BDQYGP38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 2.52% 61.00 57.00 65.00 61.00 59.50 59.50 12,246 14:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 149k -7.14M -0.1082 -5.64 39.26M

Celsis International - Rule 8 Disclosure

20/05/1998 6:21pm

UK Regulatory


RNS No 7962w
CELSIS INTERNATIONAL PLC



                         Date of disclosure  20TH MAY 1998

DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON
TAKEOVERS AND MERGERS

Date of dealing   15TH MAY 1998

Dealing in ......... CELSIS INTERNATIONAL ........(name of company)

(1)  Class of securities (eg ordinary shares) 5P ORDINARY SHARES

(2)     Amount bought          Amount sold         Price per unit

           500,000                  -                  44.50P

(3)  Resultant total of the same class owned or controlled
     (and percentage of class) ..........2,005,000 ........ (2.01%)

(4)  Party making disclosure ........ AMVESCAP PLC ................

(5)  EITHER  (a)  Name of purchaser/vendor (Note 1) ..............

     OR      (b)  If dealing for discretionary client(s), name of
                  fund management organisation

     ................... AMVESCAP PLC ............................

(6)  Reason for disclosure (Note 2)
     (a)  associate of   (i)   offeror (Note 3)         NO
                         (ii)  offeree company          NO

     Specify which category or categories of
     associate (1-8 overleaf) .....................................

     If category (8), explain ......................................
     ...............................................................
     (b)Rule 8.3 (ie disclosure because of ownership or control of
     1% or more of the class of relevant securities dealt in)YES

Signed, for and on behalf of the party named in (4) above  A. TULLY
(Also print name of signatory) ........ANGELA TULLY................

Telephone and extension number 0171-454 3652 .......................

                ----------------------------------

Note 1  Specify   owner,  not  nominee  or  vehicle   company.    If
        relevant,  also identify controller of owner,  eg  where  an
        owner normally acts on instructions of a controller.
Note 2  Disclosure  might be made for more than one reason;  if  so,
        state all reasons.
Note 3  Specify which offeror if there is more than one.
Note 4  When  an  arrangement  exists with  any  offeror,  with  the
        offeree  company or with an associate of any offeror  or  of
        the  offeree  company  in relation to  relevant  securities,
        details  of such arrangement must be disclosed, as  required
        by Note 6 on Rule 8.
Note 5  It   may   be   necessary,  particularly   when   disclosing
        derivative   transactions,  to  append  a  sheet   to   this
        disclosure  form  so  that all relevant information  can  be
        given.
Note 6  In  the  case  of an average price bargain, each  underlying
        trade should be disclosed.



For full details of disclosure requirements, see Rule 8 of the Code.
If in doubt, contact the Panel on Takeovers and Mergers, Tel. No.
0171-382 9026.


END 

DCCMLGZKNGVLRMM


1 Year Celadon Pharmaceuticals Chart

1 Year Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart